The PROMISE study
Faecal Microbiota Transplantation (FMT) to reduce susceptibility to infections resulting in hospitalisation for patients with liver disease. The human body creates inflammation to fight infection. Our gut contains trillions of bacteria (or bugs), often referred to as...
Green light for new liver cirrhosis trial using engineered immune cells
A new UK clinical trial will “supercharge” patients’ own immune cells to help their livers recover. The EMERALD trial (Evaluating Macrophages Engineered to Resolve Advanced Liver Disease), will see if people with advanced liver cirrhosis can benefit from...
New digital “prehab” service for people waiting for a liver transplant
A liver transplant is a major operation. To be on the transplant list, patients must be both sick enough to need a new liver and well enough to cope with the surgery. The South West liver unit at University Hospitals Plymouth has now teamed up with telehealth company...
The OPAL study
Trial status: Closed to recruitment in the UK Trial ID: NCT06380335 What is OPAL? OPAL is an observational study sponsored by Resolution Therapeutics. 11 hospitals across England and Scotland are participating in the study. OPAL stands for Observational Study in...